Education > Article > Bio.Clear™ Endotox-LV | Research

Bio.Clear™ Endotox-LV | Research

The liver is an important organ that affects multiple systems in the body; indeed, it is seen as the most important organ in many cultures. In product development we were drawn to the liver because it is a primary site for lipopolysaccharide (LPS) clearance. To create a product to optimise liver function, was therefore high on our priority list.

An Introduction

People with liver pathology have been shown to have a higher amount of circulating LPS due to reduced liver functioning and increased intestinal permeability (1, 2). Moreover, the degree of endotoxemia is correlated with the degree of liver failure (3).

LPS, also referred to as endotoxins, are large molecules that consist of a lipid and polysaccharide joined together. They are an important constituent of gram-negative bacteria and cyanobacteria cell walls and are released in large numbers when the cell is broken down or the colony grows in large amounts (4).

Gram-negative bacteria are commensal inhabitants in our microbiome and in small amounts they play an important role in building our innate immunity (5). However, LPS are able to initiate a vigorous inflammatory response. Indeed, they are so effective at inducing inflammation in the body, that they are often the basis of creating inflammatory models in research trials (6). In high quantities LPS in the blood can lead to septicaemia, but exposure to high levels of LPS is also indicated as a driving factor in many other inflammatory disorders, such as metabolic syndrome, liver and renal diseases, chronic obstructive pulmonary disease, cardiovascular disease, autoimmunity and neurodegenerative disorders, amongst others (4,7-10). In order to tightly regulate our exposure to them, we have developed a strong immune response. Central to this, is the liver.

LPS pathway

Fig 1. One pathway of lipopolysaccharide (LPS) signalling in Kupffer cells.
Adapted from Su, G. (12).


The liver is the final barrier to prevent GI bacteria and bacterial products such as LPS and other toxins from entering the systemic blood stream (11). Bile is part of this strategy as it is a potent antimicrobial agent (12). The liver is also the primary site of excretion, since LPS are treated as lipoproteins in the body.

In addition to LPS clearance, the liver is a key site of LPS sampling and immune initiation. Kupffer cells reside in the liver sinusoids, which drain blood from the GI tract, therefore they are chronically exposed to LPS. LPS activate Kupffer cells primarily by three mechanisms: increasing expression of CD14, TLR-4 binding, and binding to LPS binding protein (LPB) which is produced by hepatocytes (See Fig 1). The resultant initiation of cytokines, including IL-8 and TNF-a, eicaosanoids, nitric oxide, and reactive oxygen intermediates via NF-kB translocation, aids the immune response to, and clearance of, LPS (13).


  1. Nakatani Y, Fukui H, Kitano H, Nagamoto I, Tsujimoto T, Kuriyama S, et al. Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis. Liver. 2001;21(1):64–70.
  2. Deng M, Scott MJ, Loughran P, Gibson G, Sodhi C, Watkins S, et al. Lipopolysaccharide Clearance, Bacterial Clearance, and Systemic Inflammatory Responses Are Regulated by Cell Type-Specific Functions of TLR4 during Sepsis. J Immunol. 2013;190(10):5152–60.
  3. Bigatello LM, Broitman SA, Fattori L, Di Paoli M, Pontello M, Bevilacqua G, Nespoli A. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am J Gastroenterol. 1987 Jan;82(1):11-5.
  4. Stewart I, Schluter PJ, Shaw GR. Environmental Health : A Global Cyanobacterial lipopolysaccharides and human health – a review. 2006;23:1–23
  5. Rosadini C V., Kagan JC. Early innate immune responses to bacterial LPS. Curr Opin Immunol. 2017;44:14–9.
  6. DellaGioia N, Hannestad J. A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci Biobehav Rev. 2010;34(1):130–43.
  7. Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3(4):759–91.
  8. Nakatani Y, Fukui H, Kitano H, Nagamoto I, Tsujimoto T, Kuriyama S, et al. Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis. Liver. 2001;21(1):64–70.
  9. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic Endotoxemia. 2007;56(July):1761–72.
  10. Ngkelo A, Meja K, Yeadon M, Adcock I, Kirkham PA. LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and G iα dependent PI-3kinase signalling. J Inflamm. 2012;9:2–8
  11. Nakao A, Taki S, Yasui M, Kimura Y, Nonami T, Harada A, Takagi H. The fate of intravenously injected endotoxin in normal rats and in rats with liver failure. Hepatology. 1994;19(5):1251-6.
  12. Su G., Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. American J Physiol Gastro & Liver Physiol/ 2002; 283(2):G256-G265.
  13. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42(2):145–51.

Related Articles

Bio.Clear, Bio.Me, GI Microbiome, Immunology & Inflammation
Optimising Your Immune System

To help optimise immunity, it is imperative that we nourish the immune system from the outside-in and inside-out with an emphasis on nurturing our relationship with the microbial colonies with ...

Bio.Clear, Bio.Me
Introducing The Bio.Revive™ Range

Bio.Revive™ is a range of plant and nutrient-based therapeutics designed to restore homeostasis and optimise the body's functions.

Bio.Clear, GI Microbiome
New Bio.Clear™ Microbia GI

Our new anti-microbial botanical blend for dysbiotic microbiome(s)